In the world of drug development, the leap from concept to clinic is often a long and winding road. But Creative Biolabs is quietly reshaping that journey—one assay, one chip, one insight at a time.

Activation of the complement cascade of proteases has been linked to autoimmune and kidney diseases, including systemic lupus ...

Innate Immunity is a nonspecific host defense mechanism against foreign antigens. It is the first line of defense in a host and occurs immediately or within hours after exposure. This type of immunity ...

Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H'23 DNTH103 is a next-generation monoclonal ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects ...

Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.